AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32406312
Drug: High sodium
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High sodium intake (3900 mg Na+/day)
Trial: 33027800
Drug: Medical Nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical Nutrition Therapy (MNT) for 12 weeks, involving 6 appointments with registered dietitians.
Trial: 33027800
Drug: Medical Nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical Nutrition Therapy (MNT) group
Trial: 35705150
Drug: Fluid restriction
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid restriction (1500 mL/day)
Trial: 36441736
Drug: Intranasal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal placebo (INP)
Trial: 33714860
Drug: SOX (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOX (100 mg/m2 of oxaliplatin on day 1 and 80 mg/m2/day of S‐1 on days 1‐14, every 21 days, eight cycles)
Trial: 33714860
Drug: UFT/LV (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT/LV (300 mg/m2 of UFT and 75 mg/day of LV on days 1‐28, every 35 days, five cycles)
Trial: 32219623
Drug: MAKS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAKS treatment
Trial: 35751307
Drug: Lidocaine hydrochloride
RxNorm normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine hydrochloride 2 mg/kg bolus dose
Trial: 35751307
Drug: 0.9% normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline continuous intravenous infusion
Trial: 32797700
Drug: Needle tip
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle tip identification before injection
Trial: 32797700
Drug: Failure to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Failure to identify the needle tip before injection
Trial: 34583659
Drug: Theory-based drug-use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theory-based drug-use prevention program (10 sessions of 45 minutes each)
Trial: 34583659
Drug: Traditional didactic
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional didactic teaching and drug refusal skill training
Trial: 34583659
Drug: Theory-based drug-use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theory-based drug-use prevention program
Trial: 32298326
Drug: 18-week exercise
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 18-week exercise intervention during chemotherapy
Trial: 36805707
Drug: Inhaled prostacyclin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled prostacyclin
Trial: 33228736
Drug: Corticosteroids (monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (monthly intravenous methylprednisolone pulses or daily oral prednisolone)
Trial: 33228736
Drug: Clobazam (oral)
RxNorm normalized name: Clobazam
DrugBank: Clobazam (DB00349)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clobazam (oral)
Trial: 35848625
Drug: Mobile application
RxNorm normalized name: Mahana IBS CBT Mobile Application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile application in addition to standard management (short counseling session and 1-month course of oral iron therapy)
Trial: 35848625
Drug: Standard management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard management (short counseling session and 1-month course of oral iron therapy)
Trial: 34236436
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g OBG (oat β-glucan) 3 times daily for 4 weeks
Trial: 35235030
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection IS nerve block of 10 cc (133 mg) liposomal bupivacaine mixed with 10 cc of 0.5% bupivacaine (Group 1)
Trial: 35235030
Drug: Continuous indwelling
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous indwelling IS nerve block catheter delivering 0.2% ropivacaine at a continual 4 cc/h infusion for the initial 3 post-operative days (Group 2)
Trial: 35150880
Drug: Intravenous posaconazole
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous posaconazole therapy followed by oral therapy (200 mg once daily after day 12)
Trial: 35150880
Drug: Oral posaconazole
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral posaconazole therapy (400 mg twice daily on day 1, followed by 400 mg once daily)
Trial: 34293446
Drug: Clofazimine with
RxNorm normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clofazimine with a median of 3 concomitant antibiotics
Trial: 32525925
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy for 3 months
Trial: 34933066
Drug: Twice-weekly hemodialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly hemodialysis with adjuvant pharmacologic therapy for 6 weeks followed by thrice-weekly hemodialysis (incremental HD group)
Trial: 34933066
Drug: Thrice-weekly hemodialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-weekly hemodialysis (conventional HD group)
Trial: 34669886
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein supplementation (40 g daily for 15 days)
Trial: 34669886
Drug: Casein supplementation
RxNorm normalized name: caseins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casein supplementation (40 g daily for 15 days)
Trial: 33155296
Drug: OLS models
RxNorm normalized name: limonen-10-ol, (+)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OLS models estimating SACE for periodontal treatment
Trial: 32594760
Drug: Vasoactive intestinal
RxNorm normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasoactive intestinal polypeptide (VIP) infusion
Trial: 34495425
Drug: OMDI 0.002%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMDI 0.002% once daily (Group 1 and Group 2)
Trial: 34495425
Drug: OMDI 0.002%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMDI 0.002% once daily + timolol 0.5% twice daily (Group 3)
Trial: 34495425
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (timolol 0.5% twice daily)
Trial: 32065601
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate prehydration (250 mL of 1.4% sodium bicarbonate administered in a 1-hour infusion)
Trial: 35841512
Drug: Smartphone application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone application promoting preschooler's oral health
Trial: 35841512
Drug: Common oral
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common oral health education (educational pamphlet and verbal explanations)
Trial: 33421647
Drug: Propranolol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (2 mg intravenous)
Trial: 35921102
Drug: Active tDCS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active tDCS group (30-minute daily sessions for 4 weeks, 2 mA anodal-right and cathodal-left prefrontal stimulation)
Trial: 32006422
Drug: Low sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sodium diet (2.6 g/day)
Trial: 32006422
Drug: Medium sodium
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium sodium diet (6.0 g/day)
Trial: 32006422
Drug: High sodium
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High sodium diet (18.0 g/day)
Trial: 32382556
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine (DEX)
Trial: 34269813
Drug: Azithromycin (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (1.2 g single oral dose)
Trial: 34617558
Drug: MOS-supplemented infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOS-supplemented infant formula (7.2 g MOS/L)
Trial: 32888340
Drug: Ziprasidone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone (10 mg)
Trial: 32888340
Drug: Ziprasidone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone (20 mg)
Trial: 33650469
Drug: Golimumab concentration
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Golimumab concentration < 1.0 mg/L
Trial: 33650469
Drug: Golimumab concentration
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Golimumab concentration 1.0–3.9 mg/L
Trial: 33650469
Drug: Golimumab concentration
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Golimumab concentration ≥ 4.0 mg/L
Trial: 33650469
Drug: Serum golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Serum golimumab concentration < 1.0 mg/L
Trial: 33650469
Drug: Golimumab concentrations
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Golimumab concentrations ≥ 1.0 mg/L
Trial: 32558624
Drug: Intragastric infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intragastric infusion of fructose (25g)
Trial: 38939496
Drug: Atorvastatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (80 mg/d)
Trial: 33016036
Drug: Protopine and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protopine and Nuciferine syrup, 10 ml, once a day, for 8 weeks
Trial: 33016036
Drug: Placebo (flavoured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (flavoured coloured water), 10 ml, once a day, for 8 weeks
Trial: 32842367
Drug: One shot
RxNorm normalized name: Acetaminophen 650 mg in 50 mL ORAL LIQUID [Headache Man No More Pills, One Shot, Headache Pain Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One shot of carboplatin (76 mg/kg, i.p.)
Trial: 32842367
Drug: Two shots
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two shots of carboplatin (76 mg/kg, i.p., one-week interval)
Trial: 32755104
Drug: Alcohol dose
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol dose 0.06%
Trial: 32755104
Drug: Alcohol dose
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol dose 0.08%
Trial: 34322853
Drug: Prolonged-release fampridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release fampridine (PR-FAM) 10-mg tablet twice daily
Trial: 32465771
Drug: IVIG +
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG + conventional antimicrobial therapy
Trial: 32465771
Drug: Conventional antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antimicrobial therapy alone
Trial: 32017092
Drug: Lactobacillus reuteri-containing
RxNorm normalized name: Lactobacillus reuteri-containing product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri-containing lozenges (test group, n=36)
Trial: 34460425
Drug: Lactulose:mannitol (L:M)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose:mannitol (L:M) test
Trial: 33928883
Drug: Deutetrabenazine (fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deutetrabenazine (fixed-dose 12-36 mg)
Trial: 33928883
Drug: Deutetrabenazine (flexible-dose)
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deutetrabenazine (flexible-dose)
Trial: 33387497
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy plus S-1
Trial: 34622767
Drug: All biologic
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All biologic agents
Trial: 33198070
Drug: Treatment modality
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment modality for RPI
Trial: 36438075
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) plus low-dose aspirin treatment (Group A = 85)
Trial: 36438075
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin treatment only (Group B = 88)
Trial: 36438075
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) plus low-dose aspirin treatment (Group A)
Trial: 34424549
Drug: Piroctone olamine
RxNorm normalized name: Piroctone Olamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroctone olamine (PO) containing leave-on treatment
Trial: 32022904
Drug: Restrictive fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive fluid therapy regimen
Trial: 33186729
Drug: Intranasal Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal Fentanyl (INF)
Trial: 33562001
Drug: Traditional slimming
RxNorm normalized name: arched swimming crab, cooked preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional slimming therapies using an individual diet plan and dietitian’s care
Trial: 34357781
Drug: Exemestane 25
RxNorm normalized name: exemestane 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane 25 mg by mouth once daily and entinostat 5 mg by mouth once weekly (EE)
Trial: 34357781
Drug: Exemestane 25
RxNorm normalized name: exemestane 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane 25 mg by mouth once daily and placebo 5 mg by mouth once weekly (EP)
Trial: 34184336
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron preoperatively
Trial: 34184336
Drug: No intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intravenous iron (control group)
Trial: 32358640
Drug: Probiotic (AminoAlta™,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic (AminoAlta™, a multi-strain probiotic with 5 billion CFU L. paracasei LP-DG® and 5 billion CFU L. paracasei LPC-S01)
Trial: 35666289
Drug: Fesoterodine 4
RxNorm normalized name: fesoterodine 4 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine 4 mg (continuous usage)
Trial: 35666289
Drug: Fesoterodine 4
RxNorm normalized name: fesoterodine 4 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine 4 mg (on-demand usage)
Trial: 34242498
Drug: Normobaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normobaric oxygen (NBO) at 8 L/min
Trial: 32255318
Drug: Removal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Removal of nephrotoxic agents
Trial: 35668503
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with nicotine patch
Trial: 35668503
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with sham nicotine patch
Trial: 35668503
Drug: Sham acupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham acupuncture combined with nicotine patch
Trial: 35668503
Drug: Sham acupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham acupuncture combined with sham nicotine patch
Trial: 35789530
Drug: Lifestyle modification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle modification combined with TEAS four times weekly for 12 weeks
Trial: 33832145
Drug: Both PRF
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both PRF stimulation and physical therapy
Trial: 33789009
Drug: Sotatercept 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotatercept 0.3 mg/kg every 3 weeks
Trial: 33789009
Drug: Sotatercept 0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotatercept 0.7 mg/kg every 3 weeks
Trial: 32331034
Drug: Pimavanserin (PIM)
DrugBank: Pimavanserin (DB05316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimavanserin (PIM) 34 mg/day
Trial: 36175968
Drug: Low-dose titrated
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose titrated morphine hydrochloride administered intravenously for 24 hours
Trial: 36175968
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% NaCl) administered for 24 hours
Trial: 33371126
Drug: Basic western
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic western medicine treatment
Trial: 33339609
Drug: Alfacalcidol 2
RxNorm normalized name: Alfacalcidol 250 nanogram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol 2 μg/d started 48 hours before surgery and continued throughout the hospital stay
Trial: 33339609
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no alfacalcidol treatment)
Trial: 32223112
Drug: Apixaban (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban (10 mg twice daily for the first 7 days, followed by 5 mg twice daily)
Trial: 32223112
Drug: Dalteparin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin (200 IU per kilogram once daily for the first month, followed by 150 IU per kilogram once daily)
Trial: 34402789
Drug: Chemi Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemi Enoxaparin (80 mg/0.8 mL)
Trial: 34402789
Drug: Clexane (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clexane (80 mg/0.8 mL)
Trial: 35869734
Drug: Clostridium butyricum
RxNorm normalized name: Clostridium butyricum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clostridium butyricum capsules combined with rosuvastatin
Trial: 36207156
Drug: Aqua Maris
RxNorm normalized name: Aqua Maris
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqua Maris Extra Strong irrigation therapy in addition to standard therapy
Trial: 36207156
Drug: Aqua Maris
RxNorm normalized name: Aqua Maris
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqua Maris Extra Strong irrigation therapy
Trial: 33761717
Drug: Combined music
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined music therapy + Tai Chi
Trial: 33761717
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy alone
Trial: 32383801
Drug: Pharmacist intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist intervention (medication reconciliation at discharge with a link to the community pharmacist)
Trial: 34772399
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of erythropoietin (EPO) 4000 IU/ml for 2 minutes before graft placement
Trial: 34772399
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of erythropoietin (EPO) 4000 IU/ml
Trial: 34600629
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise (subsymptom threshold), at least 20 min daily for up to 4 weeks
Trial: 34600629
Drug: Stretching exercise
RxNorm normalized name: Mederma Stretch Mark Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stretching exercise (placebo-like), at least 20 min daily for up to 4 weeks
Trial: 34214220
Drug: Fractional radiofrequency
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional radiofrequency microneedling monotherapy (group B)
Trial: 33221326
Drug: Abicipar 2
RxNorm normalized name: abicipar pegol
DrugBank: Abicipar Pegol (DB12258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abicipar 2 mg every 8 weeks (abicipar Q8, n=630)
Trial: 33221326
Drug: Abicipar 2
RxNorm normalized name: abicipar pegol
DrugBank: Abicipar Pegol (DB12258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abicipar 2 mg every 12 weeks (abicipar Q12, n=628)
Trial: 33221326
Drug: Ranibizumab 0.5
RxNorm normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.5 mg every 4 weeks (ranibizumab Q4, n=630)
Trial: 34920097
Drug: OC‐01 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC‐01 0.03 mg
Trial: 34920097
Drug: OC‐01 0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC‐01 0.06 mg
Trial: 32598243
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose intravenous (i.v.) antibiotic